title: [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
abstract: Management of genitourinary (GU) cancers is improving rapidly with the development of immunotherapy agents, especially anti-PD-1/anti-PD-L1 therapies. Large studies have shown better outcomes for the treatment of these patients, leading to new drug approvals and recent changes in standards of care in renal, prostate and bladder cancer. We performed a review of recent studies assessing efficacy of immuno-oncology therapies in GU cancers. New results are summarized and next ways of development of clinical research are discussed as the use of such therapies will soon be assessed in first-line or adjuvant settings.
authors.affiliation: University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department and Department of Medical Oncology, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Bigot
authors.affiliation: University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department and Department of Medical Oncology, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Bonnet
authors.affiliation: University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department and Department of Medical Oncology, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. Electronic address: christophe.massard@gustaveroussy.fr.
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive / Q000379:methods; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D011471:Prostatic Neoplasms / Q000628:therapy*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014565:Urogenital Neoplasms / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019496:Cancer Vaccines; D061026:Programmed Cell Death 1 Receptor; C000613593:durvalumab; D000077594:Nivolumab; C000594389:atezolizumab; C582435:pembrolizumab; C000609138:avelumab
keywords: Cancers génito-urinaires; Genitourinary cancer; Immunotherapy; Immunothérapie; Review; Revue